Clay Siegall’s role in Cancer Treatment

National Cancer Institute states that about 40 percent of women and men in the U.S will at one point of their life be diagnosed with some form of cancer. Over 600,000 people lost their cancer battles in U.S alone. Given these shocking statistics, it is obvious to feel like there is little that is being done about this terrible disease, but that is not the case. Biotech firms like the Seattle genetics are pushing the cancer treatment and research boundaries with men like Clay Siegall at their top. Their commitment enables them to make significant progress in the field.

Dr.Clay Siegall is the CEO and founder of Seattle Genetics, a biotech firm based in Seattle that specializes in targeted therapy drugs development for the types of diseases that have not seen any substantial mortality improvements in decades. He holds a B.S in Zoology from the University of Maryland and a genetics Ph. D. from Gorge Washington University.

Since he established the Seattle Genetic back in 1998, Dr. Siegall has led his firm to great heights in the targeted therapy industry through the development of the first FDA-approved conjugate antibody drug, which currently has multiple approved indications. Clay has also developed a robust pipeline of more than 20 drugs and some strategic partnerships with manufacturers of drugs including Genentech, Bayer, Pfizer, and others.

Seattle Genetics under the leadership of Dr. Siegall has grown from a small startup with just a few researchers to a great power player in the research space of cancer. Mr. Siegall has big plans for the future of the company. With the expanding list of the drugs in its development pipeline and an ever increasing number of prospective indications for the existing drug portfolio of the company, the firm is in an excellent position to move with authority into the 21st-century industry in drug development.

Dr. Siegall also worked with the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute. Clay is one of the Boards of Trustees of Ultrageny Pharmaceutical, Washington Round table, and Alder Bio Pharmaceuticals. Dr. Siegall has been a recipient of several awards which includes University of Maryland Alumnus of the year for Math, Natural Sciences and Computer in 2013, and the Pacific North Ernst and Young Entrepreneur of the year in 2012. He has written seventy publications and holds 15 patents.


Financial Expert David Giertz Tackles SocSec

On a recent episode of the short financial talk show, Wealth Adviser, produced and distributed by The Wallstreet Journal, noted financial expert David Giertz appeared to clear the air on the problems currently surrounding American discourse on social security. Mr. Giertz started off by saying that there was a enormous problem with in the financial advisory industry, namely that not enough financial professionals were providing their clients with enough usable information concerning social security. To back up his claim he cites a survey carried out by his organization, the Nationwide Financial Retirement Institute, which showed that of those surveyed who were ten years from retirement or already retired overwhelmingly said that they were not getting enough relevant information from their financial advisers.


Mr. Giertz stresses that this point is extremely important from both a consumer and a financial advisers perspective. For the consumer, money loss is a huge concern, for instance, if a individual coming into retirement age turns on social security too early they could be looking at a financial hit of around $ 300,000 over a 25 year period, or $ 12,000 a year or $ 1000 a month which, naturally, most people simply do not have the ability to pay.


From a financial advisers perspective their clientele retention rate his also important. After all, you can not expect your client base to stick with you with an regularity when you are not telling them all of the relevant facts they need to know for retirement to ensure that their nest egg is kept safe.